The global heart failure drugs market is estimated to grow from USD 9.19 billion in the current year to USD 12.31 billion by 2035, at a notable CAGR during the forecast period, till 2035 (this represents the opportunity only for those drugs that are primarily indicated for heart failure).
Over the years, significant advancements in drug development have expanded the range of treatment options available for heart failure management. Several therapeutic classes have received approval from the U.S. Food and Drug Administration, including angiotensin-converting enzyme (ACE) inhibitors, diuretics, angiotensin receptor blockers (ARBs), aldosterone antagonists, and beta-blockers. Continued clinical research and technological innovation have further introduced next-generation therapies and congenital heart defect devices that are transforming treatment paradigms. Notably, angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists provide broader therapeutic benefits by targeting multiple pathways associated with cardiac remodeling, fluid overload, and neurohormonal dysregulation.
The heart failure therapeutics market continues to demonstrate steady growth, supported by substantial investments in research and development by pharmaceutical companies. Ongoing innovation in novel drug mechanisms, combination therapies, and advanced drug-delivery technologies is expanding the treatment landscape and improving patient outcomes. As clinical evidence supporting these advanced therapies continues to strengthen, their adoption is expected to accelerate, creating significant opportunities for sustained market expansion over the forecast period.
As the prevalence of the condition rises significantly among individuals aged 70 years and above, the demand for more effective treatment options continues to grow. In response, pharmaceutical companies have introduced innovative drug classes, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs), which have demonstrated strong clinical efficacy in improving patient outcomes. These therapies are associated with reduced mortality rates and lower risks of heart failure-related hospitalizations, while the combined use of SGLT2 inhibitors and ARNIs has shown enhanced therapeutic benefits. Consequently, the increasing adoption of these advanced therapies is expected to support sustained growth of the heart failure therapeutics market over the coming years.
2. More than 120 drugs are currently approved / being investigated across various stages of development for the treatment and management of heart failure; of these, over 90% are under clinical development.
3. Majority (51%) of the heart failure drugs are biologics; of these, 75% of the drugs are being investigated for chronic heart failure under different stages of clinical development.
4. Clinical trials investigating drugs targeting heart failure are distributed across different geographical regions; maximum patient enrollment was observed in North America (42%), followed by Europe (34%).
5. Around 45% of the discontinued therapies were industry sponsored; of these, more than 35% of the trials were for heart failure with preserved ejection fraction.
6. The heart failure drugs market is anticipated to grow at a notable CAGR owing to the ability to improve patient outcomes through novel therapeutic mechanisms (such as SGLT2 inhibitors and other emerging classes).
7. The heart failure drugs market in North America is expected to capture maximum share by 2035, driven by a robust pharmaceutical ecosystem, high R&D investments, and accelerated regulatory approvals.
8. Driven by the growing adoption of heart failure drugs in the US, the market is poised to grow at a relatively higher CAGR over the forecast period.
Conversely, the biologics segment is anticipated to expand at a substantially higher CAGR of 52.0% during the forecast period. This growth is expected to be driven by increasing interest in precision medicine approaches, with biologics offering the potential to target genetic, molecular, and inflammatory mechanisms underlying heart failure progression. Their ability to address unmet clinical needs and command premium pricing is likely to support future market expansion.
Meanwhile, therapies administered through the intramyocardial route are expected to experience the fastest growth, registering a CAGR of 34.9% through 2035. This growth is driven by the route’s ability to deliver therapeutic agents directly to cardiac tissue, potentially enhancing treatment efficacy and improving cardiac function in patients with advanced heart failure.
However, the combination therapy segment is expected to witness stronger growth, with a projected CAGR of 34.4% over the forecast period. Increasing adoption of multidrug treatment strategies, including quadruple therapy regimens comprising ARNIs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors, is expected to drive this expansion. These combination approaches offer synergistic therapeutic effects, leading to improved clinical outcomes, reduced mortality and hospitalization rates, and enhanced disease management compared to standalone therapies.
HEART FAILURE DRUGS MARKET: GROWTH AND TRENDS
Heart failure is a progressive cardiovascular disorder characterized by the heart’s inability to pump an adequate volume of blood to meet the body's metabolic demands. The rising prevalence of this condition has prompted pharmaceutical companies to develop a broad range of therapeutic interventions aimed at managing fluid retention, enhancing cardiac function, regulating blood pressure, and addressing the underlying causes of disease progression. According to the Heart Failure Society of America, approximately 6.7 million Americans aged 20 years and older are currently living with heart failure, a figure projected to increase to 10.3 million by 2040.Over the years, significant advancements in drug development have expanded the range of treatment options available for heart failure management. Several therapeutic classes have received approval from the U.S. Food and Drug Administration, including angiotensin-converting enzyme (ACE) inhibitors, diuretics, angiotensin receptor blockers (ARBs), aldosterone antagonists, and beta-blockers. Continued clinical research and technological innovation have further introduced next-generation therapies and congenital heart defect devices that are transforming treatment paradigms. Notably, angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists provide broader therapeutic benefits by targeting multiple pathways associated with cardiac remodeling, fluid overload, and neurohormonal dysregulation.
The heart failure therapeutics market continues to demonstrate steady growth, supported by substantial investments in research and development by pharmaceutical companies. Ongoing innovation in novel drug mechanisms, combination therapies, and advanced drug-delivery technologies is expanding the treatment landscape and improving patient outcomes. As clinical evidence supporting these advanced therapies continues to strengthen, their adoption is expected to accelerate, creating significant opportunities for sustained market expansion over the forecast period.
Growth Drivers: Strategic Enablers of Market Expansion
The growth of the heart failure therapeutics market is being driven by the convergence of demographic trends and continued innovation in treatment approaches. The expanding geriatric population, coupled with the rising prevalence of age-associated risk factors such as hypertension, obesity, coronary artery disease, and diabetes, has led to a substantial increase in the incidence of heart failure worldwide.As the prevalence of the condition rises significantly among individuals aged 70 years and above, the demand for more effective treatment options continues to grow. In response, pharmaceutical companies have introduced innovative drug classes, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs), which have demonstrated strong clinical efficacy in improving patient outcomes. These therapies are associated with reduced mortality rates and lower risks of heart failure-related hospitalizations, while the combined use of SGLT2 inhibitors and ARNIs has shown enhanced therapeutic benefits. Consequently, the increasing adoption of these advanced therapies is expected to support sustained growth of the heart failure therapeutics market over the coming years.
Market Challenges: Critical Barriers Impeding Progress
Despite the growing demand for innovative heart failure therapies, the market continues to face several challenges that may impede its growth trajectory. The development of therapies for this indication is associated with high attrition rates, primarily driven by inadequate clinical efficacy, limited target specificity, and safety concerns that frequently emerge during the clinical development process.. Additionally, the approval rate of new molecular entities (NMEs) for cardiovascular indications remains relatively low, increasing both the complexity and cost of bringing novel therapies to market. These challenges are further compounded by the substantial financial requirements associated with large-scale clinical trials, stringent regulatory pathways, and patient recruitment difficulties. At the same time, limited funding support from government agencies and private investors can restrict the progression of promising research programs, creating barriers to innovation and slowing the development of next-generation heart failure treatments. Consequently, these factors continue to pose significant challenges for stakeholders operating within the heart failure therapeutics market.HEART FAILURE DRUGS MARKET: KEY INSIGHTS
The report delves into the current state of the heart failure drugs market and identifies potential growth opportunities within industry. Some key findings from the report include:
1. Owing to the rising disease prevalence and lack of selective treatment approaches, several researchers and industry stakeholders are prioritizing the development of heart failure drugs.2. More than 120 drugs are currently approved / being investigated across various stages of development for the treatment and management of heart failure; of these, over 90% are under clinical development.
3. Majority (51%) of the heart failure drugs are biologics; of these, 75% of the drugs are being investigated for chronic heart failure under different stages of clinical development.
4. Clinical trials investigating drugs targeting heart failure are distributed across different geographical regions; maximum patient enrollment was observed in North America (42%), followed by Europe (34%).
5. Around 45% of the discontinued therapies were industry sponsored; of these, more than 35% of the trials were for heart failure with preserved ejection fraction.
6. The heart failure drugs market is anticipated to grow at a notable CAGR owing to the ability to improve patient outcomes through novel therapeutic mechanisms (such as SGLT2 inhibitors and other emerging classes).
7. The heart failure drugs market in North America is expected to capture maximum share by 2035, driven by a robust pharmaceutical ecosystem, high R&D investments, and accelerated regulatory approvals.
8. Driven by the growing adoption of heart failure drugs in the US, the market is poised to grow at a relatively higher CAGR over the forecast period.
Heart Failure Drugs Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Heart Failure
- Chronic Heart Failure
- Others
By Type of Therapy
- Monotherapies
- Combination Therapies
By Type of Molecule
- Small Molecules
- Biologics
Route of Administration
- Oral
- Intramyocardial
- Subcutaneous
- Intravenous
- Intracoronary
By Geographical Regions
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of the World
HEART FAILURE DRUGS MARKET: KEY SEGMENT INSIGHTS
Which Type of Heart Failure Represents the Largest Share of the Heart Failure Drugs Market?
Currently, the chronic heart failure segment is expected to account for the overwhelming majority of the heart failure drugs market, capturing more than 95% of total revenue. This dominance is primarily attributed to the high prevalence of chronic heart failure, its lifelong disease management requirements, and the continuous need for pharmacological intervention to control symptoms and prevent disease progression. The segment is also expected to witness steady growth throughout the forecast period. Notably, Empagliflozin (Jardiance), a monotherapy approved for heart failure treatment in 2021, generated approximately USD 4.4 billion in sales in 2025, underscoring the strong commercial potential of chronic heart failure therapeutics.Regional Analysis: Which Regions are Expected to Exhibit the Strongest Growth?
North America: Maintaining Market Leadership
According to market projections, North America is expected to retain its position as the largest regional market, accounting for over 40% of the global heart failure drugs market in the current year. The region benefits from a well-established healthcare infrastructure, high disease awareness, favorable reimbursement frameworks, and significant investment in cardiovascular research. In particular, the United States has emerged as a leading hub for heart failure drug development, supported by innovation-driven regulatory policies, a robust biopharmaceutical ecosystem, and access to a highly skilled workforce. These advantages facilitate the efficient progression of therapies from early-stage development through commercialization.Asia-Pacific: Fastest-Growing Regional Market
While North America is expected to dominate in terms of market share, Asia-Pacific is projected to register the highest growth rate through 2035. Growth in the region is anticipated to be driven by a rapidly aging population, increasing prevalence of cardiovascular disorders, expanding healthcare access, and rising investments in pharmaceutical innovation.UAE Market Outlook
In the United Arab Emirates, market accessibility is expected to improve following recent initiatives by the Emirates Drug Establishment to reduce the retail prices of 168 pharmaceutical products. The price revisions include advanced therapies used in the treatment of chronic heart muscle failure, thereby supporting broader patient access to innovative heart failure medications.Which Molecule Type is Expected to Dominate the Heart Failure Drugs Market?
Small molecules are projected to remain the dominant molecule category, accounting for more than 95% of the market in the current year. Their leadership position is supported by their established efficacy, advantages associated with oral drug administration, and widespread use as the standard of care in heart failure management. Key therapeutic classes, including beta-blockers, ACE inhibitors, ARBs, and SGLT2 inhibitors, have demonstrated significant clinical benefits in reducing mortality and improving patient outcomes across both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) populations.Conversely, the biologics segment is anticipated to expand at a substantially higher CAGR of 52.0% during the forecast period. This growth is expected to be driven by increasing interest in precision medicine approaches, with biologics offering the potential to target genetic, molecular, and inflammatory mechanisms underlying heart failure progression. Their ability to address unmet clinical needs and command premium pricing is likely to support future market expansion.
Which Route of Administration Accounts for the Largest Market Share?
Based on market forecasts, oral therapies currently contribute more than 95% of total market revenue. The widespread adoption of oral formulations can be attributed to their convenience, strong patient adherence, suitability for long-term disease management, and ease of self-administration in outpatient settings.Meanwhile, therapies administered through the intramyocardial route are expected to experience the fastest growth, registering a CAGR of 34.9% through 2035. This growth is driven by the route’s ability to deliver therapeutic agents directly to cardiac tissue, potentially enhancing treatment efficacy and improving cardiac function in patients with advanced heart failure.
Among Monotherapies and Combination Therapies, Which Segment Holds the Largest Share?
Monotherapies currently account for the majority of market revenue, reflecting their long-standing role as first-line treatment options within established clinical guidelines. Their broad adoption is supported by favorable cost-effectiveness profiles, well-documented clinical outcomes, and higher patient adherence compared to more complex treatment regimens.However, the combination therapy segment is expected to witness stronger growth, with a projected CAGR of 34.4% over the forecast period. Increasing adoption of multidrug treatment strategies, including quadruple therapy regimens comprising ARNIs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors, is expected to drive this expansion. These combination approaches offer synergistic therapeutic effects, leading to improved clinical outcomes, reduced mortality and hospitalization rates, and enhanced disease management compared to standalone therapies.
Example Players in Heart Failure Drugs Market
- AstraZeneca
- Boehringer Ingelheim
- Bristol Myers Squibb
- Corteria Pharmaceuticals
- Cytokinetics
- Eli Lilly
- Hyloris Pharmaceuticals
- Jiangsu Hengrui Pharmaceuticals
- Novo Nordisk
- Sardocor
- StemCardia
- Tasly Pharmaceuticals
- Tenaya Therapeutics
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of the following third-party discussions:- Professor of Medical Cardiology, Very Large Organization, United Kingdom, Europe
- Professor and Head of Advanced Heart Failure Wing, Very Large Organization, United States, North America
- Clinical Associate Professor and Director of Clinical Research, Large Organization, United States, North America
- Doctor of Medicine, Very Large Organization, United States, North America
- Professor, Very Large Organization, United States, North America
- Professor of Medicine and Heart Failure Specialist (Former Chair of Division for Circulatory Failure), Very Large Organization, United States, North America
- Senior Consultant Cardiologist, Large Organization, India, Asia
- Chair of DIGIT-HF trial, Very Large Organization, Germany, Europe
- Cardiologist and Clinical Researcher, Very Large Organization, United States, North America
HEART FAILURE DRUGS MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the heart failure drugs market, focusing on key market segments, including [A] type of heart failure, [B] type of therapy, [C] type of molecule, [D] route of administration, [E] geographical regions, and [F] sales forecast.
- Market Landscape: A detailed assessment of the overall heart failure drugs market landscape, featuring information on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] type of biologic, [D] type of therapy, [E] mechanism of action, [F] route of administration, [G] target patient population, [H] type of heart failure, [I] year of establishment, [J] company size, [K] location of headquarters and [L] most active players.
- Company Profiles: In-depth profiles of key drug developers in the heart failure drugs market, focusing on [A] company overview, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
- Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to heart failure drugs, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of sponsor / collaborator, [F] patient gender, [G] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [H] leading industry and non-industry players (based on number of clinical trials) and [I] geography.
- Drug Failure Analysis: An insightful drug failure analysis, based on several parameters, such as [A] trial phase, [B] trial status, [C] reason of drug discontinuation, [D] study start year, [E] year of discontinuation, [F] type of molecule, and [G] route of administration.
- Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
KEY QUESTIONS ANSWERED IN THIS REPORT
- Which are the leading companies in the heart failure drugs market?
- Which region dominates the heart failure drugs market?
- What are the key trends observed in the heart failure drugs market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by heart failure drug developers?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
ADDITIONAL BENEFITS
- Complementary Excel Data Packs for all Analytical Modules in the Report
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. BACKGROUND
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
5. EXECUTIVE SUMMARY
6. INTRODUCTION
7. MARKET LANDSCAPE
8. COMPANY PROFILES
9. CLINICAL TRIAL ANALYSIS
10. DRUG FAILURE ANALYSIS
11. MARKET IMPACT ANALYSIS
12. GLOBAL HEART FAILURE MARKET
13. HEART FAILURE MARKET, BY TYPE OF HEART FAILURE
14. HEART FAILURE MARKET, BY TYPE OF THERAPY
15. HEART FAILURE MARKET, BY TYPE OF MOLECULE
16. HEART FAILURE MARKET, BY ROUTE OF ADMINISTRATION
17. HEART FAILURE MARKET, BY GEOGRAPHICAL REGIONS
18. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
19. MARKET OPPORTUNITY ANALYSIS: EUROPE
20. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
21. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD
22. HEART FAILURE MARKET, SALES FORECAST OF DRUGS
24. EXECUTIVE INSIGHTS
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- abbott
- atricure
- bostonscientific
- bms
- cadrenal
- daiichisankyo
- jnj
- medtronic
- novartis
- sanofi
Methodology
LOADING...
